Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593884 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL29775131 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL83474 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL163841 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL1161605 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL674106 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL3216510 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL5635861 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL163842 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL29777394 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| US-20210060040-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | claimed |
| US-10632134-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2020-04-28 | — | — | US | claimed |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | claimed |
| CN-110709085-A | Compounds and methods for treating visceral pain | 艾尼纳制药公司 | 2020-01-17 | — | — | CN | claimed |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | claimed |
| EP-3385252-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-10-10 | — | — | EP | claimed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-20170304327-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | claimed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | claimed |
| EP-0828702-B1 | PROCESS FOR RESOLVING CHIRAL ACIDS WITH 1-AMINOINDAN-2-OLS | SEPRACOR INC (US) | 2000-08-30 | — | — | EP | claimed |
| EP-0828702-A1 | PROCESS FOR RESOLVING CHIRAL ACIDS WITH 1-AMINOINDAN-2-OLS | SEPRACOR, INC. (US) | 1998-03-18 | — | — | EP | claimed |
| US-5677469-A | PREPARING MIXTURE OF CHIRAL ACID AND ENANTIOMER OF AMINOINDANOL IN SOLVENT, SEPARATING DIASTEREOMERIC SALT, RECOVERING CHIRAL ACID | SEPRACOR, INC. (US) | 1997-10-14 | — | — | US | claimed |
| EP-0719247-A4 | PROCESS FOR PREPARING CYCLIC CIS-1-AMINO-2-ALKANOLS | SEPRACOR INC (US) | 1997-04-02 | — | — | EP | claimed |
| US-5616808-A | Optically pure 1-amino-2-indanols | SEPRACOR, INC. (US) | 1997-04-01 | — | — | US | claimed |
| US-5599985-A | Optically pure 1-amido-2-indanols | SEPRACOR, INC. (US) | 1997-02-04 | — | — | US | claimed |
| WO-1996036584-A1 | PROCESS FOR RESOLVING CHIRAL ACIDS WITH 1-AMINOINDAN-2-OLS | SEPRACOR, INC. (US) | 1996-11-21 | — | — | WO | claimed |
| EP-0719247-A1 | PROCESS FOR PREPARING CYCLIC CIS-1-AMINO-2-ALKANOLS | SEPRACOR, INC. (US) | 1996-07-03 | — | — | EP | claimed |
| WO-1995007880-A1 | PROCESS FOR PREPARING CYCLIC CIS-1-AMINO-2-ALKANOLS | SEPRACOR, INC. (US) | 1995-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | SLC6A3, OPRK1, HTR3A | ANPEP 2552/4885KDM1A 3480/4885HTR2A 132/4885 |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | ANPEP 2194/4885KDM1A 1799/4885HTR2A 506/4885 |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | ANPEP 4731/4885KDM1A 2127/4885HTR2A 536/4885 |
| US-10632134-B2 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | ANPEP 4453/4885KDM1A 2336/4885HTR2A 72/4885 |
| US-20210060040-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | ANPEP 4453/4885KDM1A 2336/4885HTR2A 72/4885 |
| US-20170304327-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | ANPEP 4453/4885KDM1A 2336/4885HTR2A 72/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | ANPEP 2194/4885KDM1A 1799/4885HTR2A 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.